Retatrutide (LY-3437943) is a synthetic peptide designed as a triple incretin receptor agonist with simultaneous activity at the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This multi-receptor pharmacology distinguishes it from single- and dual-agonist peptides in its class. In preclinical and experimental research, Retatrutide is examined as a model compound for studying multi-target receptor activation, metabolic pathway crosstalk, and incretin biology. Laboratory investigations explore its receptor binding profiles, downstream cAMP and insulin signaling cascades, and energy expenditure markers in in-vitro receptor assays and in-vivo metabolic models. The triple-agonist mechanism provides a research platform for studying how simultaneous engagement of GLP-1R, GIPR, and GCGR influences glucose homeostasis, hepatic lipid metabolism, and energy balance pathways in controlled experimental systems. CAS: 2381089-83-2 Molecular Weight: ~4,113 Da Supplied at 20mg for controlled laboratory research. Not for human consumption.